Genomic prediction of response and resistance to PARP inhibition in breast cancer

乳腺癌对 PARP 抑制反应和耐药性的基因组预测

• 批准号: 301439
• 负责人: Hassan Saima N
• 金额: $ 8.74万
• 依托单位: Oregon Health & Science University (Portland)
• 依托单位国家: 加拿大
• 项目类别: Fellowship Programs
• 财政年份: 2013
• 资助国家: 加拿大
• 起止时间: 2013-11-01 至 2015-11-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=301439&lang=en
• 关键词: Breast Cancer; Dna Damage Pathways; Integrated Genomic Characterization; Microenvironment Model; Parp Inhibition; Predictive Biomarkers; Therapeutic Response; Therpeutic Resistance

Although new treatments have helped improve the survival of breast cancer patients, the development of new therapies is challenging. Only a small number of therapeutic agents tested in the laboratory have demonstrated efficacy in patients. Laboratory mod

虽然新的治疗方法有助于提高乳腺癌患者的生存率，但新疗法的开发仍具有挑战性。 只有少数在实验室测试的治疗药物在患者中表现出疗效。实验室模式